MX2022011336A - Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos. - Google Patents

Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos.

Info

Publication number
MX2022011336A
MX2022011336A MX2022011336A MX2022011336A MX2022011336A MX 2022011336 A MX2022011336 A MX 2022011336A MX 2022011336 A MX2022011336 A MX 2022011336A MX 2022011336 A MX2022011336 A MX 2022011336A MX 2022011336 A MX2022011336 A MX 2022011336A
Authority
MX
Mexico
Prior art keywords
interference mitigation
drug antibody
antibody assay
target interference
systems
Prior art date
Application number
MX2022011336A
Other languages
English (en)
Inventor
Albert Torri
Jihua Chen
Sumner Giane Oliveira
Kimberly Kendra
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022011336A publication Critical patent/MX2022011336A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

La presente invención proporciona métodos y sistemas para detectar, cuantificar o caracterizar anticuerpos antifármacos que se inducen con la administración de productos farmacéuticos. Los métodos y sistemas incluyen el uso de un compañero de unión de una diana y/o un cofactor para mejorar la detección de anticuerpos antifármacos en muestras de suero con dianas solubles según la unión competitiva a la diana. Los métodos y sistemas también incluyen el uso del inmunoagotamiento para mejorar la detección.
MX2022011336A 2020-03-17 2021-03-16 Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos. MX2022011336A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062990681P 2020-03-17 2020-03-17
PCT/US2021/022623 WO2021188587A1 (en) 2020-03-17 2021-03-16 Target interference mitigation in anti-drug antibody assay

Publications (1)

Publication Number Publication Date
MX2022011336A true MX2022011336A (es) 2022-10-07

Family

ID=75581604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011336A MX2022011336A (es) 2020-03-17 2021-03-16 Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos.

Country Status (11)

Country Link
US (1) US20210293811A1 (es)
EP (1) EP4121775A1 (es)
JP (2) JP7735299B2 (es)
KR (1) KR20220156023A (es)
CN (1) CN115667935A (es)
AU (1) AU2021237564A1 (es)
BR (1) BR112022018034A2 (es)
CA (1) CA3177634A1 (es)
IL (1) IL296424A (es)
MX (1) MX2022011336A (es)
WO (1) WO2021188587A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022912A2 (pt) * 2018-07-10 2021-02-23 Regeneron Pharmaceuticals, Inc. métodos para mitigar a interferência de alvo de fármaco em um imunoensaio de anticorpo antifármaco (ada)
CN114047343B (zh) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用
JP2025523802A (ja) * 2022-07-13 2025-07-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分析物を検出するための弱酸性免疫アッセイ
CN116699147A (zh) * 2023-08-04 2023-09-05 军科正源（北京）药物研究有限责任公司 检测总IgE含量的方法以及相关试剂盒
WO2025261427A1 (zh) * 2024-06-20 2025-12-26 启光德健医药科技(苏州)有限公司 用于评估抗体免疫激动剂偶联物产生ada的方法及其应用
CN119881340B (zh) * 2025-03-26 2025-08-12 军科正源（北京）药物研究有限责任公司 检测抗HBV preS1单抗候选药物中和抗体的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022001A1 (en) * 2007-08-16 2009-02-19 Novartis Ag Improvement of drug tolerance in immunogenicity testing
BR112020022912A2 (pt) * 2018-07-10 2021-02-23 Regeneron Pharmaceuticals, Inc. métodos para mitigar a interferência de alvo de fármaco em um imunoensaio de anticorpo antifármaco (ada)

Also Published As

Publication number Publication date
KR20220156023A (ko) 2022-11-24
JP7735299B2 (ja) 2025-09-08
AU2021237564A1 (en) 2022-10-06
EP4121775A1 (en) 2023-01-25
US20210293811A1 (en) 2021-09-23
IL296424A (en) 2022-11-01
CN115667935A (zh) 2023-01-31
JP2025176059A (ja) 2025-12-03
BR112022018034A2 (pt) 2022-10-18
CA3177634A1 (en) 2021-09-23
JP2023517751A (ja) 2023-04-26
WO2021188587A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MX2022011336A (es) Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos.
MX2024013186A (es) Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo
MX344053B (es) Metodos para determinar isotipos de anticuerpos anti-farmacos.
NO20076662L (no) Deteksjon av et malantigen uavhengig av tilstedevaerelse eller fravaer av et korresponderende terapeutisk antistoff
BR112015032960A8 (pt) imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
EA202190237A1 (ru) Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada)
HK1207421A1 (en) Methods and systems for detecting an analyte or classifying a sample
ZA202002415B (en) Detection of symmetrical dimethylarginine
WO2020037250A3 (en) Stem-loop receptor-based field-effect transistor sensor devices target detection for small-molecule under physiological salt concentrations
GB2404022B (en) Competitive assays for the detection of methamphetamine group drugs
EP4354146A3 (en) Immunoassay for the detection of cleaved high molecular weight kininogen
WO2012159072A3 (en) Fluorescent molecular probes for use in assays that measure test compound competitive binding with sam-utilizing proteins
MX353566B (es) Metodos y sistemas para amplificacion de señal de bioensayos.
MX2022013738A (es) Ensayo de anticuerpos neutralizantes para proteinas terapeuticas.
EA201370030A1 (ru) Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням
MY150966A (en) Lateral flow device and method of detection of nucleic acid sequence
MX2025009067A (es) Metodos para cuantificar la il-33
WO2005114218A3 (en) Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
MX2009012048A (es) Eliminacion de interferencia en inmunoensayos ocasionada por anticuerpos de anti-carbohidrato.
NZ603340A (en) Yeast cell wall components and detection thereof
Lin et al. Sensitive and reliable micro-plate chemiluminescence enzyme immunoassay for okadaic acid in shellfish
RU2014140135A (ru) Мультиплексный иммунохроматографический способ определения циркулирующих иммунокомплексов
WO2016112261A3 (en) Assay to detect human dpp-4
MX2025008774A (es) Sistema y metodo de analisis de coformulaciones de anticuerpos